RAD202
Radiopharmaceutical
Evidence outlook
Early-stage evidence only
Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT06824155 NCT06824155 · HER2-Positive Advanced Solid Tumors Registry: NCT06824155 | 1 | Safety and tolerability of 177Lu-RAD202 (6 weeks); Recommended dose(s) of 177Lu-RAD202 for future exploration (6 weeks) 2027-12 | In progress: results expected 1 Dec 2027 | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 1 (1)
What this study did
Competitive landscape
Other HER2 drugs
margetuximab, Trastuzumab Deruxtecan, Tucatinib, Zanidatamab, Disitamab Vedotin and 11 more. Compare all 17 HER2 drugs
This mechanism is crowded: 16 other tracked programmes target it, 10 of them ahead of this one.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| RAD202: this drug | Phase 1 | Radiopharmaceutical | HER2 | not yet graded | No reviewed efficacy summary | |
| Margetuximab (Margenza) | Approved(overall) | Monoclonal antibody | HER2 | not yet graded | No reviewed efficacy summary | |
| Trastuzumab Deruxtecan | Approved(overall) | Antibody–drug conjugate | HER2 | Partial signal | NCT04494425: Progression-Free Survival (PFS) Assessed by Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Low Population (Response evaluations performed at screening, every 6 weeks (q6w) ± 1 week from randomization for 48 weeks, and then every 9 weeks (q9w) ± 1 week, starting at Week 48 until PD, up to PCD of 18 March 2024 (maximum of approximately 43.85 months)): T-DXd 13.2 months (95% CI 11.4 to 15.2) | Chemotherapy 8.1 months (95% CI 7 to 9) NCT03523585: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Trastuzumab Deruxtecan (T-DXd) 17.8 months (95% CI 14.3 to 20.8) | |
| Tucatinib | Approved(overall) | Small molecule | HER2 | Reliable signal | NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001. NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1) | |
| Zanidatamab | Approved(overall) | Multispecific antibody | HER2 | Weak signal | NCT04466891: Confirmed ORR 41.3% (95% CI 30.4-52.8); median duration of response 12.9 months (Lancet Oncol 2023) | |
| Disitamab Vedotin | Phase 3(overall) | Antibody–drug conjugate | HER2 | Partial signal | NCT03500380: Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91). NCT03052634: Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months | |
| Trastuzumab Brengitecan | Phase 3(overall) | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary | |
| Trastuzumab Pamirtecan | Phase 3(overall) | Antibody–drug conjugate | HER2 | Partial signal | NCT06265428: NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis. | |
| Trastuzumab Rezetecan | Phase 3(overall) | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary | |
| Bizrolertinib | Phase 2/3(overall) | Small molecule | HER2 | not yet graded | No reviewed efficacy summary | |
| HRS-4508 | Phase 2(overall) | Small molecule | HER2 | not yet graded | No reviewed efficacy summary | |
| 177Lu-DWJ155 | Phase 1(overall) | Radiopharmaceutical | HER2 | not yet graded | No reviewed efficacy summary | |
| BL-M17D1 | Phase 1(overall) | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary | |
| KJ015 | Phase 1(overall) | Multispecific antibody | HER2 | not yet graded | No reviewed efficacy summary | |
| MT-304 | Phase 1(overall) | RNA / oligonucleotide | HER2 | not yet graded | No reviewed efficacy summary | |
| NVL-330 | Phase 1(overall) | Small molecule | HER2 | not yet graded | No reviewed efficacy summary | |
| GSK6855547 | —(overall) | Small molecule | HER2 | not yet graded | No reviewed efficacy summary |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow RAD202 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.